A Study of TQB2930 for Injection Monotherapy or Combination Therapy in Patients With Recurrent/Metastatic Breast Cancer

This trial tests a new antibody-drug conjugate called TQB2930 — a treatment that delivers chemotherapy directly to cancer cells — alone or in combination, for people with breast cancer that has spread (metastatic) and has come back or stopped responding to prior therapy. **You may be eligible if...** - You have advanced or metastatic breast cancer that is HER2-positive and hormone receptor (HR)-negative - You have not yet received treatment for your metastatic disease (or no more than 2 lines of hormonal therapy) - You are between 18 and 75 years old - You have at least one measurable tumor on imaging - Your general health is adequate (ECOG 0–1) **You may NOT be eligible if...** - You have had another cancer in the last 3 years - You have cancer spread to the brain (active or untreated) - You have had major surgery, a blood clot, or significant injury in the last 28 days - You have serious heart disease - You are pregnant or breastfeeding - You received chemotherapy, radiation, or immunotherapy within 4 weeks of enrollment Talk to your doctor to see if this trial is right for you.